Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease

Journal of Neuroscience

Volumn 29, Issue 37, 2009, Pages 11550-11559

  Dai, Ying ^a,c   Dudek, Nichole L ^b   Li, Qian ^c   Fowler, Stephen C ^c   Muma, Nancy A ^c  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALMODULIN; HUNTINGTIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOPRECIPITATION; MALE; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CALMODULIN; CORPUS STRIATUM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GAIT; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GREEN FLUORESCENT PROTEINS; GTP-BINDING PROTEINS; HUNTINGTON DISEASE; IMMUNOPRECIPITATION; LOCOMOTION; MALE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PEPTIDE FRAGMENTS; ROTAROD PERFORMANCE TEST; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSGLUTAMINASES; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 70349105129     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3307-09.2009     Document Type: Article

References (55)

1. Bao J, Sharp AH, Wagster MV, Becher M, Schilling G, Ross CA, Dawson VL, Dawson TM (1996) Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A 93:5037-5042. (Pubitemid 26163505)
2. Beal MF, Ferrante RJ (2004) Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 5:373-384. (Pubitemid 38568498)
3. Billett HH, Puszkin EG (1991) The red cell membrane contains calmodulin-regulated crosslinking and proteolytic activity. Hematol Pathol 5:185-193.
4. Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 19:3248-3257. (Pubitemid 29174016)
5. Cheung WY (1982) Role of calmodulin in brain function. Prog Brain Res 56:237-253.
6. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P, Housman DE, Kazantsev A, Young AB, Hersch S (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc Natl Acad Sci U S A 104:16685-16689. (Pubitemid 350211077)
7. Cooper AJ, Sheu KF, Burke JR, Strittmatter WJ, Gentile V, Peluso G, Blass JP (1999) Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability. J Neurochem 72:889-899. (Pubitemid 29085002)
8. Cyr M, Caron MG, Johnson GA, Laakso A (2005) Magnetic resonance imaging at microscopic resolution reveals subtle morphological changes in a mouse model of dopaminergic hyperfunction. Neuroimage 26:83-90. (Pubitemid 40602888)
9. Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22:8942-8950. (Pubitemid 35379064)
10. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993. (Pubitemid 27449140)
11. Dudek NL, Dai Y, Muma NA (2008) Protective effects of interrupting the binding of calmodulin to mutant huntingtin. J Neuropathol Exp Neurol 67:355-365.
12. Dudek NL, Dai Y, Muma NA (2009) Neuroprotective effects of calmodulin peptide 76-121aa: disruption of calmodulin binding to mutant huntingtin. Brain Pathol. Advance online publication. Retrieved March 10, 2009. doi:10.1111/j.1750-3639.2008.00258.x
13. Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 20:4389-4397. (Pubitemid 30396603)
14. Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599. (Pubitemid 35386278)
15. Folk JE, Park MH, Chung SI, Schrode J, Lester EP, Cooper HL (1980) Polyamines as physiological substrates for transglutaminases. J Biol Chem 255:3695-3700.
16. Fowler SC, Birkestrand BR, Chen R, Moss SJ, Vorontsova E, Wang G, Zarcone TJ (2001) A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods 107:107-124. (Pubitemid 32487615)
17. Franklin KBJ, Paxinos G (1997) The mouse brain in stereotaxic coordinates. San Diego: Academic.
18. Gentile V, Sepe C, Calvani M, Melone MA, Cotrufo R, Cooper AJ, Blass JP, Peluso G (1998) Tissue transglutaminase-catalyzed formation of high-molecular- weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch Biochem Biophys 352:314-321.
19. Gray M, Shirasaki DI, Cepeda C, André VM, Wilburn B, Lu XH, Tao J, Yamazaki I, Li SH, Sun YE, Li XJ, Levine MS, Yang XW (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 28:6182-6195.
20. Griffin M, Casadio R, Bergamini CM (2002) Transglutaminases: nature's biological glues. Biochem J 368:377-396.
21. Hampton TG, Stasko MR, Kale A, Amende I, Costa AC (2004) Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol Behav 82:381-389. (Pubitemid 38981625)
22. Handley OJ, Naji JJ, Dunnett SB, Rosser AE (2006) Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin Sci (Lond) 110:73-88. (Pubitemid 43059046)
23. Harper PS (1991) Huntington's disease. London: Saunders.
24. Hersch SM, Ferrante RJ (2004) Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx 1:298-306. (Pubitemid 46589358)
25. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983. (Pubitemid 23110238)
26. Kahlem P, Green H, Djian P (1998) Transglutaminase action imitates Huntington's disease: selective polymerization of Huntingtin containing expanded polyglutamine. Mol Cell 1:595-601. (Pubitemid 128374695)
27. Kalchman MA, Koide HB, McCutcheon K, Graham RK, Nichol K, Nishiyama K, Kazemi-Esfarjani P, Lynn FC, Wellington C, Metzler M, Goldberg YP, Kanazawa I, Gietz RD, Hayden MR (1997) HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet 16:44-53.
28. Karpuj MV, Garren H, Slunt H, Price DL, Gusella J, Becher MW, Steinman L (1999) Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc Natl Acad Sci U S A 96:7388-7393. (Pubitemid 29299671)
29. Karpuj MV, Becher MW, Steinman L (2002a) Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int 40:31-36. (Pubitemid 34003556)
30. Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L (2002b) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8:143-149. (Pubitemid 34155125)
31. Kazantsev A, Walker HA, Slepko N, Bear JE, Preisinger E, Steffan JS, Zhu YZ, Gertler FB, Housman DE, Marsh JL, Thompson LM (2002) A bivalent Huntingtin binding peptide suppresses polyglutamine aggregation and pathogenesis in Drosophila. Nat Genet 30:367-376. (Pubitemid 34887661)
32. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC (2002) Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A 99:10671-10676. (Pubitemid 34907035)
33. Lesort M, Chun W, Johnson GV, Ferrante RJ (1999) Tissue transglutaminase is increased in Huntington's disease brain. J Neurochem 73: 2018-2027. (Pubitemid 29491816)
34. Li H, Li SH, Johnston H, Shelbourne PF, Li XJ (2000) Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25:385-389. (Pubitemid 32983427)
35. Li XJ, Li SH, Sharp AH, Nucifora FC Jr, Schilling G, Lanahan A, Worley P, Snyder SH, Ross CA (1995) A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378:398-402.
36. Lloret A, Dragileva E, Teed A, Espinola J, Fossale E, Gillis T, Lopez E, Myers RH, MacDonald ME, Wheeler VC (2006) Genetic background modifies nuclear mutant huntingtin accumulation and HD CAG repeat instability in Huntington's disease knock-in mice. Hum Mol Genet 15:2015-2024. (Pubitemid 43983275)
37. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87:493-506. (Pubitemid 26374323)
38. Mastroberardino PG, Iannicola C, Nardacci R, Bernassola F, De Laurenzi V, Melino G, Moreno S, Pavone F, Oliverio S, Fesus L, Piacentini M (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9:873-880.
39. Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR (2000) Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening. J Biol Chem 275:10437-10442. (Pubitemid 30202104)
40. Norlund MA, Lee JM, Zainelli GM, Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 851:154-163.
41. Perutz MF, Johnson T, Suzuki M, Finch JT (1994) Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355-5358. (Pubitemid 24174325)
42. Petersen A, Mani K, Brundin P (1999) Recent advances on the pathogenesis of Huntington's disease. Exp Neurol 157:1-18. (Pubitemid 29226865)
43. Puszkin EG, Raghuraman V (1985) Catalytic properties of a calmodulin-regulated transglutaminase from human platelet and chicken gizzard. J Biol Chem 260:16012-16020.
44. Ross CA, Margolis RL, Becher MW, Wood JD, Engelender S, Cooper JK, Sharp AH (1998) Pathogenesis of neurodegenerative diseases associated with expanded glutamine repeats: new answers, new questions. Prog Brain Res 117:397-419. (Pubitemid 28530703)
45. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, Borchelt DR (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8:397-407. (Pubitemid 29097327)
46. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I (2003) Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 39:227-239.
47. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I (2009) Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci 29:1257-1266.
48. Tucholski J, Kuret J, Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73:1871-1880. (Pubitemid 29491800)
49. Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR (2006) Body weight is modulated by levels of full-length huntingtin. Hum Mol Genet 15:1513-1523.
50. Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR (2007) Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol Dis 26:189-200. (Pubitemid 46436497)
51. von Hörsten S, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, et al (2003) Transgenic rat model of Huntington's disease. Hum Mol Genet 12:617-624. (Pubitemid 36372488)
52. Wanker EE (2000) Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol Chem 381:937-942. (Pubitemid 30784520)
53. Zainelli GM, Ross CA, Troncoso JC, Muma NA (2003) Transglutaminase cross-links in intranuclear inclusions in Huntington disease. J Neuropathol Exp Neurol 62:14-24. (Pubitemid 36068889)
54. Zainelli GM, Ross CA, Troncoso JC, Fitzgerald JK, Muma NA (2004) Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci 24:1954-1961.
55. Zainelli GM, Dudek NL, Ross CA, Kim SY, Muma NA (2005) Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3. J Neuropathol Exp Neurol 64:58-65.